

Resource Summary Report

Generated by [PRECISE-TBI](#) on Aug 9, 2026

CD8

RRID:AB_2739421

Type: Antibody

Proper Citation

BD Biosciences Cat# 565968, RRID:AB_2739421

Antibody Information

URL: http://antibodyregistry.org/AB_2739421

Proper Citation: BD Biosciences Cat# 565968, RRID:AB_2739421

Target Antigen: CD8a

Host Organism: rat

Clonality: monoclonal

Comments: Applications: Flow cytometry

Antibody Name: CD8

Description: This monoclonal targets CD8a

Target Organism: mouse

Clone ID: 53-6.7

Antibody ID: AB_2739421

Vendor: BD Biosciences

Catalog Number: 565968

Record Creation Time: 20250820T054050+0000

Record Last Update: 20250820T221145+0000

Ratings and Alerts

No rating or validation information has been found for CD8.

No alerts have been found for CD8.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 18 mentions in open access literature.

Listed below are recent publications. The full list is available at [PRECISE-TBI](#) .

Hasegawa M, et al. (2026) Tolerance to extracellular acidic pH facilitates tumor plasticity. Cell reports, 117226.

Rozalén C, et al. (2025) TIM3+ breast cancer cells license immune evasion during micrometastasis outbreak. Cancer cell, 43(8), 1549.

Hesterberg RS, et al. (2025) Lymphoma accelerates T cell and tissue aging. Cancer cell.

Larsen RK, et al. (2025) Non-cell-autonomous tumor promotion in DICER1 cancer predisposition. Developmental cell.

Kwok T, et al. (2025) Macrophage repolarization by immune checkpoint blockade drives T cell engagement in the tumor microenvironment. iScience, 28(10), 113538.

Park J, et al. (2025) MYC plus class IIa HDAC inhibition drives mitochondrial dysfunction in non-small cell lung cancer. Cell reports, 44(6), 115722.

Ziblat A, et al. (2024) Batf3+ DCs and the 4-1BB/4-1BBL axis are required at the effector phase in the tumor microenvironment for PD-1/PD-L1 blockade efficacy. Cell reports, 43(5), 114141.

Diehl C, et al. (2024) Hyperreactive B cells instruct their elimination by T cells to curb autoinflammation and lymphomagenesis. Immunity.

Jaeger-Ruckstuhl CA, et al. (2024) Signaling via a CD27-TRAF2-SHP-1 axis during naive T cell activation promotes memory-associated gene regulatory networks. Immunity, 57(2), 287.

Houbaert D, et al. (2024) An autophagy program that promotes T cell egress from the lymph node controls responses to immune checkpoint blockade. Cell reports, 43(4), 114020.

van Elsas MJ, et al. (2024) Immunotherapy-activated T cells recruit and skew late-stage activated M1-like macrophages that are critical for therapeutic efficacy. Cancer cell, 42(6), 1032.

Redford SE, et al. (2023) CD4+ T cells regulate sickness-induced anorexia and fat wasting during a chronic parasitic infection. Cell reports, 42(8), 112814.

van Elsas MJ, et al. (2023) Invasive margin tissue-resident macrophages of high CD163 expression impede responses to T cell-based immunotherapy. Journal for immunotherapy

of cancer, 11(3).

Popović B, et al. (2023) Time-dependent regulation of cytokine production by RNA binding proteins defines T cell effector function. *Cell reports*, 42(5), 112419.

Hernández-Malmierca P, et al. (2022) Antigen presentation safeguards the integrity of the hematopoietic stem cell pool. *Cell stem cell*, 29(5), 760.

Wilson AS, et al. (2022) Neutrophil extracellular traps and their histones promote Th17 cell differentiation directly via TLR2. *Nature communications*, 13(1), 528.

Fitzgerald B, et al. (2021) A mouse model for the study of anti-tumor T cell responses in Kras-driven lung adenocarcinoma. *Cell reports methods*, 1(5).

Bortoluzzi S, et al. (2021) Brief homogeneous TCR signals instruct common iNKT progenitors whose effector diversification is characterized by subsequent cytokine signaling. *Immunity*, 54(11), 2497.